Forbes Article "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems"

Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. Click the below to access the fill Forbes article.

Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems (forbes.com)

Link to Nature Communications publication on the PRV Platform is also provided below.

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer | Nature Communications

Media Contact: communicationteam@privotechnologies.com

September 8, 2022

Author

'Peter Goldberg'

10DecDecember 10, 2016

Privo Technologies receives 2015 TechConnect Innovation Award

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

07SepSeptember 7, 2019

FDA Grants $2 million award to Privo Technologies to expedite its clinical trial

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

06JunJune 6, 2019

BIO International Convention

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

01AugAugust 1, 2015

Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more